# Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

> **NCT06438822** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil

## Key facts

- **NCT ID:** NCT06438822
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-30
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06438822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06438822, "Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06438822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*